BioXcel Therapeutics, Inc. (BTAI) — Earnings Call X-Ray
Our AI read all 26 of BTAI's earnings calls (2018–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
F
Q2 2024
Calls Analyzed
26
2018–2024
Avg Candor
5.8/9
evasion 3.7/9
Call-by-call analysis
🔒 Q3 2024 earnings call
2024-11-14
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q3 2024 call grade is ready
The full 37-point AI read of BTAI's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
F
Q2 2024 earnings call
2024-08-09
Management held guidance steady against accelerating demand. The delivery was rich in specifics.
Guidance: maintainedDemand: acceleratingPricing: stableHeadcount: cutting 4 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging✓ Early product, fast growth⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q1 2024 earnings call
2024-05-09
Management raised guidance against accelerating demand. The delivery was rich in specifics, promotional in tone.
Guidance: raisedDemand: acceleratingPricing: stableHeadcount: cutting 6 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q4 2023 earnings call
2024-03-12
Management gave no formal guidance against contracting margins.
Margins: contractingPricing: stableHeadcount: cuttingCapex: decreasing 7 analysts · 17 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q3 2023 earnings call
2023-11-14
Management held guidance steady against contracting margins. The delivery was rich in specifics, promotional in tone.
Guidance: maintainedMargins: contractingPricing: stableHeadcount: cuttingCapex: decreasing 8 analysts · 23 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q2 2023 earnings call
2023-08-14
Management lowered guidance against contracting margins. The delivery was unusually candid, frequently evasive, visibly under pressure.
Guidance: loweredMargins: contractingPricing: stableHeadcount: cutting 10 analysts · 19 questions
⚑ Critic ammunition⚑ Question left hangingFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
F
Q1 2023 earnings call
2023-05-08
Management held guidance steady against accelerating demand and contracting margins. The delivery was rich in specifics, promotional in tone.
Guidance: maintainedDemand: acceleratingMargins: contractingBacklog: growingPricing: stableHeadcount: growing 8 analysts · 19 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead✓ Early product, fast growth⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q4 2022 earnings call
2023-03-09
Management gave no formal guidance against contracting margins. The delivery was frequently evasive, promotional in tone.
Margins: contractingPricing: stableHeadcount: growing 9 analysts · 22 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q3 2022 |
2022-11-10 |
D |
none | accelerating | unclear |
6/9 |
3/9 |
| Q2 2022 |
2022-08-09 |
D |
maintained | unclear | contracting |
6/9 |
3/9 |
| Q1 2022 |
2022-05-09 |
F |
none | unclear | unclear |
5/9 |
5/9 |
| Q4 2021 |
2022-03-10 |
F |
none | unclear | contracting |
6/9 |
5/9 |
| Q3 2021 |
2021-11-10 |
F |
none | unclear | unclear |
6/9 |
4/9 |
| Q2 2021 |
2021-08-10 |
C |
none | unclear | contracting |
6/9 |
3/9 |
| Q1 2021 |
2021-05-10 |
D |
none | stable | contracting |
6/9 |
4/9 |
| Q4 2020 |
2021-03-11 |
C |
none | unclear | unclear |
6/9 |
2/9 |
| Q3 2020 |
2020-11-12 |
B |
none | unclear | contracting |
7/9 |
2/9 |
| Q2 2020 |
2020-08-14 |
C+ |
none | stable | contracting |
7/9 |
3/9 |
| Q1 2020 |
2020-05-12 |
D |
maintained | unclear | contracting |
6/9 |
4/9 |
| Q4 2019 |
2020-03-09 |
C |
none | unclear | unclear |
6/9 |
2/9 |
| Q3 2019 |
2019-11-14 |
C |
none | unclear | contracting |
6/9 |
2/9 |
| Q2 2019 |
2019-08-10 |
C+ |
none | unclear | contracting |
6/9 |
2/9 |
| Q1 2019 |
2019-05-12 |
D |
maintained | unclear | contracting |
6/9 |
4/9 |
| Q4 2018 |
2019-03-07 |
D |
none | unclear | contracting |
5/9 |
3/9 |
| Q3 2018 |
2018-11-09 |
D |
none | unclear | contracting |
5/9 |
2/9 |
| Q2 2018 |
2018-08-12 |
D |
none | unclear | contracting |
6/9 |
3/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of BTAI's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
D
Q2 2022 earnings call
2022-08-09
2 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← BT All “B” companies
BTBIF →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.